Panel urges use of Johnson & Johnson vaccine
A U.S. health panel says it’s time to resume use of Johnson & Johnson’s COVID-19 vaccine, despite a very rare risk of blood clots. Out of nearly 8 million people vaccinated before the U.S. suspended J&J’s shot, health officials uncovered 15 cases of a highly unusual kind of blood clot, three of them fatal. All were women, most younger than 50.
But advisers to the Centers for Disease Control and Prevention said Friday the vaccine’s benefits outweigh that serious but small risk — especially against a virus that’s still infecting tens of thousands of Americans every day. The government will rapidly weigh that recommendation in deciding next steps.
New York state officials gave their support for the vaccine on Saturday.
“World-renowned public health experts from the federal government and our own independent state task force have reviewed the data and reaffirmed that the use of the Johnson & Johnson vaccine can resume,” said state Gov. Andrew Cuomo. “The state of New York will resume administration of this vaccine at all of our state-run sites effective immediately. The vaccine is the weapon that will win the war against COVID and allow everyone to resume normalcy, and we have three proven vaccines at our disposal. I urge every New Yorker to take whichever one is available to them first. The sooner we all get vaccinated, the sooner we can put the long COVID nightmare behind us once and for all.”
State Health Commissioner Dr. Howard Zucker noted: “The data has shown the vaccine’s known benefits far outweigh the potential and extremely rare risks, but we urge anyone with questions about the COVID-19 vaccines to speak with their healthcare provider. We will continue to communicate regular updates and guidance from the federal government to providers and the general public about the Johnson & Johnson vaccine and all vaccines on the market.